ÇѼ³Èñ ¸íÀÇ

¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÁ¦ ½Å¾à Àӻ󿬱¸

ÇѼ³Èñ ¸íÀÇ

  • ¼Ò ¼Ó
    °Ç±¹´ëÇб³º´¿ø ½Å°æ°ú
  • Àü¹®ºÐ¾ß
    ¾ËÃ÷ÇÏÀ̸Ӻ´, ÅðÇ༺³úÁúȯ ½Å¾à °³¹ß, Àå¼öÀÇÇÐ

´ëÇÑÄ¡¸ÅÇÐȸ¸¦ ⸳ÇÑ Ä¡¸Å ¿¬±¸ ºÐ¾ßÀÇ ±ÇÀ§ÀÚ·Î ÅðÇ༺³úÁúȯ°ú ¾ËÃ÷ÇÏÀ̸Ӻ´À» Àü°øÇÑ ÀǰúÇÐÀÚÀÌÀÚ ½Å°æ°ú Àü¹®ÀÇÀÌ´Ù.
¹Ì±¹ µàÅ©´ëÇÐ ¾ËÃ÷ÇÏÀ̸Ӻ´¿¬±¸¼Ò¿¡¼­ ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ±âÃÊ¿¬±¸¸¦, ¿ö½ÌÅÏ´ëÇÐ ¾ËÃ÷ÇÏÀ̸Ӻ´¿¬±¸¼Ò¿¡¼­ Àӻ󿬱¸¸¦ ±×¸®°í ÀϺ» ±¹¸³Àå¼öÀÇ·á ¿¬±¸¼¾ÅÍ¿¡¼­ Ç÷°ü¼º Ä¡¸Å¿¬±¸¸¦ ¼öÇàÇÏ¿© ±¹³»¿ÜÀûÀ¸·Î ¿¬±¸ ¾÷ÀûÀ» ÀÎÁ¤¹Þ°í ÀÖ´Ù. ´ëÇÑÄ¡¸ÅÇÐȸ¸¦ ÂûÀÔÇÏ¿© ÃÊ´ë ȸÀå, ÀÌ»çÀåÀ» ¿ªÀÓÇÏ¿´´Ù. °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпøÀå, °Ç±¹´ëÇб³ º´¿øÀå, °Ç±¹´ëÇб³ ÀÇ·á¿øÀå °â Àǹ«ºÎÃÑÀåÀ» ¿ªÀÓÇÏ¿´À¸¸ç, Ä¡¸Å ¿Í ³ëÀÎÁúȯ °ü¸®¿Í ¿¹¹æ¿¡ °üÇÑ °ø·Î·Î 2003³â º¹ÁöºÎÀå°ü ǥâ, 2009³â ´ëÅë·É ǥâÀ» ¼ö»óÇÏ¿´´Ù. 2016³â ´ëÇѹα¹ÀÇÇÐÇѸ²¿ø Á¤È¸¿øÀ¸·Î ¼±ÃâµÇ¾úÀ¸¸ç ÇöÀç °Ç±¹´ëÇб³ ¸í¿¹±³¼ö ¹× °Ç±¹´ëÇб³º´¿ø ÀÚ¹®±³¼ö·Î ȯÀÚÁø·á¿Í ¿¬±¸¸¦ °è¼ÓÇϰí ÀÖ°í ¼¼°è À¯¼ö Á¦¾à»çµéÀÌ °³¹ßÁßÀÎ ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡·áÁ¦ÀÇ ±¹Á¦ Àӻ󿬱¸¿¡ Âü¿©Çϰí ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ Çлç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¼®»ç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °Ç±¹´ëÇб³º´¿ø ÀÚ¹®±³¼ö
  • úÞ) °Ç±¹´ëÇб³º´¿ø ½Å°æ°ú ±³¼ö
  • 2018-2019 °Ç±¹´ëÇб³ ÀÇ·á¿øÀå
  • 2016-2019 °Ç±¹´ëÇб³ Àǹ«ºÎÃÑÀå
  • 2011-2019 °Ç±¹´ëÇб³ ÀÇ»ý¸í°úÇпøÀå
  • 2012-2016 °Ç±¹´ëÇб³º´¿ø º´¿øÀå
  • 2012 °Ç±¹´ëÇб³º´¿ø ¿¬±¸ºÎ¿øÀå
  • 2011-2012 °Ç±¹´ëÇб³º´¿ø ÀÓ»óÀÇÇבּ¸¼ÒÀå
  • 2009-2011 °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ´ëÇпøÀå
  • 2004-2005 Washington University in St. Louis Alzheimer's Disease Center ¿¬±¸ ±³¼ö
  • 1989-2005 ÃæºÏ´ëÇб³ Àǰú´ëÇÐ ±³¼ö

¼ö»ó³»¿ª

Awards List
  • ´ëÅë·É»ó (2009)
  • º¸°Çº¹ÁöºÎÀå°ü»ó (2003)

ÇÐȸȰµ¿

Academic activities
  • 1996 ~ 2002´ëÇÑÄ¡¸Å¿¬±¸È¸ ȸÀå
  • 2002 ~ 2006´ëÇÑÄ¡¸ÅÇÐȸ ȸÀå
  • 2008 ~ 2012´ëÇÑÄ¡¸ÅÇÐȸ ÀÌ»çÀå
  • 2016 ~ 2018´ëÇѳëÀνŰæÀÇÇÐȸ ȸÀå
  • 2016 ~ ÇöÀç´ëÇѹα¹ÀÇÇÐÇѸ²¿ø Á¤È¸¿ø
ÇѼ³Èñ ¸íÀÇÀÇ Ä¡¸Å °ÆÁ¤ ¾ø´Â ÇູÇÑ ³ëÈÄ
´ëÇ¥¼­Àû

ÇѼ³Èñ ¸íÀÇÀÇ Ä¡¸Å °ÆÁ¤ ¾ø´Â ÇູÇÑ ³ëÈÄ

  • ÀúÀÚ(±Û)ÇѼ³Èñ
  • ÃâÆÇ»ç¿¹¹®¾ÆÄ«À̺ê
  • ¹ßÇàÀÏ2018³â 09¿ù 20ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 7°Ç
Á¦ ¸ñ ³ª Ä¡¸Å ¾Æ³Ä?
ÃâÆÇ»ç ½ÎÀÌÇÁ·¹½º ¹ßÇàÀÏ 2013³â
Á¦ ¸ñ Ä¡¸Å, À½½ÄÀÌ ´äÀÌ´Ù. Ä¡¸Å¸¦ ¿¹¹æÇØÁÖ´Â 48°¡Áö ³ú °Ç°­½Ä
ÃâÆÇ»ç ½ÎÀÌÇÁ·¹½º ¹ßÇàÀÏ 2020³â
Á¦ ¸ñ ÇѼ³Èñ ¸íÀÇÀÇ Ä¡¸Å °ÆÁ¤ ¾ø´Â ÇູÇÑ ³ëÈÄ
ÃâÆÇ»ç ¿¹¹®¾ÆÄ«ÀÌºê ¹ßÇàÀÏ 2018³â
Á¦ ¸ñ ºÎ¸ð´ÔÀ» À§ÇÑ µÎ³ú üÁ¶: È­Åõ ½ºÆ¼Ä¿ ºÙÀ̱â&»öÄ¥Çϱâ: ¿¹¹æÆí
ÃâÆÇ»ç ½ÎÀÌÇÁ·¹½º ¹ßÇàÀÏ 2022³â
Á¦ ¸ñ ºÎ¸ð´ÔÀ» À§ÇÑ µÎ³ú üÁ¶: È­Åõ ½ºÆ¼Ä¿ ºÙÀ̱â&»öÄ¥Çϱâ(Ä¡¸Å ½ÇÀü Æí)
ÃâÆÇ»ç ½ÎÀÌÇÁ·¹½º ¹ßÇàÀÏ 2022³â
Á¦ ¸ñ ºÎ¸ð´ÔÀ» À§ÇÑ µÎ³ú üÁ¶: Ãß¾ïÀÇ ¹°°Ç ½ºÆ¼Ä¿ ºÙÀ̱â&»öÄ¥Çϱâ(Ä¡¸Å ½ÇÀü Æí)
ÃâÆÇ»ç ½ÎÀÌÇÁ·¹½º ¹ßÇàÀÏ 2022³â
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ GSP1-111 Modulates the Microglial M1/M2 Phenotype by Inhibition of Toll-like Receptor 2: A Potential Therapeutic Strategy for Depression.
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Int. J. Mol. Sci.
Á¦ ¸ñ Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö J Cereb Blood Flow Metab
Á¦ ¸ñ A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa?? Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer's Disease Already Receiving Donepezil (ROMEO-AD)
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Neurol Ther
Á¦ ¸ñ Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Int J Mol Sci
Á¦ ¸ñ A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö J Clin Neurol
Á¦ ¸ñ Whole Exome Sequencing Reveals a Novel APOE Mutation in a Patient With Sporadic Early-Onset Alzheimer's Disease.
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Front Neurol
Á¦ ¸ñ Magnetic susceptibility in the deep gray matter may be modulated by apolipoprotein E4 and age with regional predilections: a quantitative susceptibility mapping study.
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Neuroradiology

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

»ê¹ßÇü ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ °¡Àå °­·ÂÇÑ À§ÇèÀÎÀÚ·Î ¾Ë·ÁÁø APOE Áö´Ü¹éÀ¯ÀüÀÚ ¹ß°ß¿¬±¸¿¡ Âü¿©ÇÏ¿© ´Ù¼ö ³í¹® ¹ßÇ¥ÇÔ. ½ÇÁ¦·Î APOE À¯ÀüÀÚÇüÀº ¾ËÃ÷ÇÏÀ̸Ӻ´ ¿øÀÎÄ¡·áÁ¦ÀÎ Ç׾ƹзÎÀ̵å´Ü°¡Ç×ü Åõ¿©½Ã ºÎÀÛ¿ë ¿¹ÃøÀÎÀÚ·Î ½Å¾à Ä¡·á¿¡µµ ÀÓ»óÀû Áֿ뼺ÀÌ È®ÀεÊ

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚ°¡ ¾Î°í ÀÖ´Â ÁúȯÀº ´ëºÎºÐ À¯ÀüÀû ¿øÀÎ º¸´Ù´Â º»ÀÎÀÌ Æò»ý À¯ÁöÇÑ »ýȰ¹æ½Ä°ú ȯ°æÀ§ÇèÀÎÀÚÀÇ »óÈ£ÀÛ¿ë °á°ú·Î ¹ß»ýµÈ °ÍÀÓÀ» ÀνĽÃŰ°í º´ÀÇ ÁøÇà ¾ïÁ¦¸¦ À§Çؼ­´Â Áö±ÝºÎÅÍ¶óµµ À߸øµÈ »ýȰ ½À°üÀ» ¹Ù·ÎÀâ´Â °ÍÀÌ ¿ì¼±À̶ó´Â °ÍÀ» °­Á¶ÇÔ

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

ȯÀÚ°¡ ¾Î°í ÀÖ´Â ÁúȯÀº ´ëºÎºÐ À¯ÀüÀû ¿øÀÎ º¸´Ù´Â º»ÀÎÀÌ Æò»ý À¯ÁöÇÑ »ýȰ¹æ½Ä°ú ȯ°æÀ§ÇèÀÎÀÚÀÇ »óÈ£ÀÛ¿ë °á°ú·Î ¹ß»ýµÈ °ÍÀÓÀ» ÀνĽÃŰ°í º´ÀÇ ÁøÇà ¾ïÁ¦¸¦ À§Çؼ­´Â Áö±ÝºÎÅÍ¶óµµ À߸øµÈ »ýȰ ½À°üÀ» ¹Ù·ÎÀâ´Â °ÍÀÌ ¿ì¼±À̶ó´Â °ÍÀ» °­Á¶ÇÔ

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°Ç±¹´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-1533
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°Ç±¹´ëÇб³º´¿øÀº »óÇã À¯¼®Ã¢ ¼±»ý²²¼­ ÀÏÁ¦ °­Á¡±âÀÎ 1931³â ¹ÎÁ·ÁöµµÀÚµé°ú ¶æÀ» ¸ð¾Æ ±¸·áÁ¦¹Î(Ï­Öûð­ÚÅ)°ú Àμúº¸±¹(ìÒâúÜÃÏÐ)ÀÇ Å« ¶æÀ» ´ã¾Æ ¼³¸³ÇÑ ¡®»çȸ¿µ Á߾ӽǺñÁø·á¿ø¡¯¿¡ »Ñ¸®¸¦ µÎ°í ÀÖ´Ù. 2002³â °Ç±¹´ëÇб³ ¼­¿ïÄ·ÆÛ½º ³²´Ü¿¡ º´¿ø °Ç¹°À» »õ·Î Áþ±â ½ÃÀÛÇØ 2005³â 8¿ù »õ·Ó°Ô žÀ¸¸ç ÁöÇÏ4Ãþ, Áö»ó 13Ãþ ¿¬¸éÀû 2¸¸ 6300¿©ÆòÀÇ »õ °Ç±¹´ëº´¿øÀº 33°³ÀÇ Áø·á°ú¿Í 784°³ÀÇ º´»ó, 9°³ÀÇ ÁßÁ¡¼¾ÅÍ¿Í 14°³ÀÇ Áø·á¼¾ÅÍ, ÇコÄɾÅ͸¦ °®Ãß°í 430¿©¸íÀÇ ÀÇ·áÁøÀÌ Áø·á¸¦ Çϰí ÀÖ´Ù. 2009³â °©»ó¼±¾Ï¼¾ÅÍ, ´ëÀå¾Ï¼¾ÅÍ, À¯¹æ¾Ï¼¾ÅÍ µî ¾Ï¼¾Å͸¦ °³¼³Çϰí, 2017³â 11¿ù¿¡´Â ÃÖ½ÅÇü ·Îº¿ ¸ðµ¨ÀÎ 4¼¼´ë ´ÙºóÄ¡Xi¸¦ µµÀÔ, ·Îº¿¼ö¼ú ¼¾ÅÍ °¡µ¿À» ½ÃÀÛÇß´Ù. °Ç±¹´ëº´¿øÀº ´ëÀå¾Ï, À¯¹æ¾Ï, Æó¾Ï, À§¾Ï, Ç÷¾×Åõ¼®, ¸¸¼ºÆó¼â¼ºÆóÁúȯ µî ÁßÁõÁúȯ ºÐ¾ß Æò°¡¿¡¼­ 1µî±ÞÀ» ±â·ÏÇϰí ÀÖÀ¸¸ç, °ñµçŸÀÓÀÌ Áß¿äÇÑ ½ÉÇ÷°üÁúȯ°ú ³úÇ÷°üÁúȯÀÇ ½Å¼ÓÁø·á½Ã½ºÅÛÀ» ¿î¿µÇÏ¸ç ±Þ¼º±â ³úÁ¹Áß ¹× °ü»óµ¿¸Æ¿ìȸ¼ú Æò°¡¿¡¼­µµ 1µî±ÞÀ» À̾°í ÀÖ´Ù. Áö³­ 2023³â¿¡´Â ÁßÁõÁúȯ Ä¡·á ¿ª·® °­È­¸¦ À§ÇØ ÁßȯÀÚ½Ç ¹× ¼ö¼ú½Ç Áõ¼³, ·Îº¿¼ö¼ú±â±â Ãß°¡ ¹× CTµî ½ÅÇüÀÇ·áÀåºñ µîÀ» µµÀÔÇß´Ù. À̾î 2024³â¿¡´Â ȯÀÚµéÀÇ ÄèÀûÇÑ È¯°æÀ» À§ÇØ º´µ¿ ȯ°æÀ» °³¼±Çϰí, 2025³â¿¡´Â ¿Ü·¡¼¾ÅÍ ÁõÃàÀ» ¾ÕµÎ°í ÀÖ´Ù.

°Ç±¹´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ±¤Áø±¸ ´Éµ¿·Î 120-1(È­¾çµ¿) °Ç±¹´ëÇб³º´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä